Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Am J Addict ; 28(2): 119-126, 2019 02.
Article in English | MEDLINE | ID: mdl-30701618

ABSTRACT

BACKGROUND AND OBJECTIVE: Methamphetamine (MA) substance use disorder (SUD) does not have an efficacious pharmacotherapy. We developed a MA vaccine and investigated its potential to attenuate MA induced responses. METHODS: We examined a novel adjuvant, E6020, a Toll-like receptor-4 (TLR-4) agonist combined with tetanus-toxoid conjugated to succinyl-methamphetamine (TT-SMA) adsorbed on aluminum hydroxide (alum). Adult BALB/c female mice received the vaccine and booster injections at weeks 0, 3, and 6. The efficacy of the vaccine was assessed by the level and affinity of anti-MA antibodies elicited, its ability to attenuate MA induced locomotor activation and its reduction in the amount of MA entering the brains of vaccinated mice. RESULTS: The TT-SMA vaccine containing alum and E6020 adjuvant produced anti-MA antibodies with nanomolar affinities and showed threefold greater peak titer levels than without E6020 (700 vs 250 µg/ml). These antibodies significantly decreased MA-induced locomotor activation (p < .05), and reduced the brain (p < .005) MA levels following MA administration in actively immunized mice. CONCLUSIONS: Thus, this anti-MA vaccine formulated with E6020 demonstrated effective functional protection against behavioral disruptions induced by MA. SCIENTIFIC SIGNIFICANCE: Together, anti-MA vaccine showing a promising improvement in the efficacy of the vaccine that could be an effective candidate vaccine for methamphetamine use disorder (MUD). Furthermore, combinations of adjuvants may be a tool to design vaccines for MA dependence in humans. (Am J Addict 2019;XX:1-8).


Subject(s)
Aluminum Hydroxide/pharmacology , Amphetamine-Related Disorders/therapy , Methamphetamine/antagonists & inhibitors , Phospholipids/pharmacology , Tetanus Toxoid/pharmacology , Adjuvants, Immunologic/pharmacology , Animals , Biological Availability , Drug Combinations , Drug Monitoring/methods , Mice , Models, Animal , Toll-Like Receptor 4/agonists , Treatment Outcome
2.
Chem Biol Drug Des ; 84(3): 354-63, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24803171

ABSTRACT

In the absence of any effective pharmacotherapy for cocaine addiction, immunotherapy is being actively pursued as a therapeutic intervention. While several different cocaine haptens have been explored to develop anticocaine antibodies, none of the hapten was successfully designed, which had a protonated tropane nitrogen as is found in native cocaine under physiological conditions, including the succinyl norcocaine (SNC) hapten that has been tested in phase II clinical trials. Herein, we discuss three different cocaine haptens: hexyl norcocaine (HNC), bromoacetamido butyl norcocaine (BNC), and succinyl butyl norcocaine (SBNC), each with a tertiary nitrogen structure mimicking that of native cocaine which could optimize the specificity of anticocaine antibodies for better cocaine recognition. Mice immunized with these haptens conjugated to immunogenic proteins produced high titre anticocaine antibodies. However, during chemical conjugation of HNC and BNC haptens to carrier proteins, the 2ß methyl ester group is hydrolyzed, and immunizing mice with these conjugate vaccines in mice produced antibodies that bound both cocaine and the inactive benzoylecgonine metabolite. While in the case of the SBNC conjugate, vaccine hydrolysis of the methyl ester did not appear to occur, leading to antibodies with high specificity to cocaine over BE. Although we observed similar specificity with a SNC hapten, the striking difference is that SBNC carries a positive charge on the tropane nitrogen atom, and therefore, it is expected to have better binding of cocaine. The 50% cocaine inhibitory concentration (IC50 ) value for SBNC antibodies (2.8 µm) was significantly better than the SNC antibodies (9.4 µm) when respective hapten-BSA was used as a substrate. In addition, antibodies from both sera had no inhibitory effect from BE. In contrast to BNC and HNC, the SBNC conjugate was also found to be highly stable without any noticeable hydrolysis for several months at 4 °C and 2-3 days in pH 10 buffer at 37 °C.


Subject(s)
Cocaine/chemistry , Haptens/chemistry , Animals , Antibodies/analysis , Antibodies/immunology , Antibodies/metabolism , Cocaine/analogs & derivatives , Cocaine/immunology , Enzyme-Linked Immunosorbent Assay , Haptens/immunology , Male , Mice , Mice, Inbred BALB C , Vaccines/immunology
3.
Expert Opin Biol Ther ; 14(9): 1271-83, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24835496

ABSTRACT

INTRODUCTION: Addiction to cocaine is a major problem around the world, but especially in developed countries where the combination of wealth and user demand has created terrible social problems. Although only some users become truly addicted, those who are often succumb to a downward spiral in their lives from which it is very difficult to escape. From the medical perspective, the lack of effective and safe, non-addictive therapeutics has instigated efforts to develop alternative approaches for treatment, including anticocaine vaccines designed to block cocaine's pharmacodynamic effects. AREAS COVERED: This paper discusses the implications of cocaine pharmacokinetics for robust vaccine antibody responses, the results of human vaccine clinical trials, new developments in animal models for vaccine evaluation, alternative vaccine formulations and complementary therapy to enhance anticocaine effectiveness. EXPERT OPINION: Robust anti-cocaine antibody responses are required for benefit to cocaine abusers, but since any reasonably achievable antibody level can be overcome with higher drug doses, sufficient motivation to discontinue use is also essential so that the relative barrier to cocaine effects will be appropriate for each individual. Combining a vaccine with achievable levels of an enzyme to hydrolyze cocaine to inactive metabolites, however, may substantially increase the blockade and improve treatment outcomes.


Subject(s)
Cocaine-Related Disorders/therapy , Cocaine/immunology , Immunotherapy/trends , Vaccines/therapeutic use , Animals , Antibodies/metabolism , Clinical Trials as Topic , Cocaine/pharmacokinetics , Cocaine-Related Disorders/immunology , Humans , Immunotherapy/methods , Protein Binding
4.
PLoS One ; 7(7): e40518, 2012.
Article in English | MEDLINE | ID: mdl-22859949

ABSTRACT

BACKGROUND: Despite progress in cocaine immunotherapy, the kinetic and thermodynamic properties of antibodies which bind to cocaine and its metabolites are not well understood. It is also not clear how the interactions between them differ in a complex matrix such as the serum present in the human body. In the present study, we have used microscale thermophoresis (MST), isothermal titration calorimetry (ITC), and surface plasmon resonance (SPR) we have evaluated the affinity properties of a representative mouse monoclonal (mAb08) as well as those of polyclonal antibodies purified from vaccinated mouse and human patient serum. RESULTS: MST analysis of fluorescently tagged mAb08 binding to cocaine reveals an approximately 15 fold decrease in its equilibrium dissociation constant in 20-50% human serum compared with that in saline buffer. A similar trend was also found using enriched polyclonal antibodies purified from vaccinated mice and patient serum, for which we have used fluorescently tagged bovine serum albumin conjugated to succinyl norcocaine (BSA-SNC). This conjugate closely mimics both cocaine and the hapten used to raise these antibodies. The ITC data also revealed that cocaine has a moderate affinity of about 2 µM to 20% human serum and very little interaction with human serum albumin or nonspecific human IgG at that concentration range. In a SPR inhibition experiment, the binding of mAb08 to immobilized BSA-SNC was inhibited by cocaine and benzoylecgonine in a highly competitive manner, whereas the purified polyclonal antibodies from vaccinated humans and mice, revealed preferential selectivity to pharmacologically active cocaine but not to the inactive metabolite benzoylecgonine. We have also developed a simple binding model to simulate the challenges associated with cocaine immunotherapy using the variable quantitative and kinetic properties of the antibodies. CONCLUSIONS: High sensitivity calorimetric determination of antibody binding to cocaine and its metabolites provide valuable information for characterization of their interactions and thermodynamic properties. In addition MST measurements of antibody affinity in the presence of biological fluids will provide a better opportunity to make reliable decisions and facilitate the design of cocaine vaccines and immunization conditions. The methods should be more widely adopted in characterization of antibody complexes.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/chemistry , Cocaine/analogs & derivatives , Cocaine/immunology , Serum/chemistry , Animals , Antibodies, Monoclonal, Murine-Derived/immunology , Antibody Affinity , Binding, Competitive , Calorimetry , Cattle , Cocaine/chemistry , Cocaine-Related Disorders/immunology , Cocaine-Related Disorders/therapy , Humans , Immobilized Proteins/chemistry , Immunotherapy , Kinetics , Mice , Protein Binding , Serum Albumin/chemistry , Serum Albumin, Bovine/chemistry , Surface Plasmon Resonance
5.
PLoS One ; 5(1): e8813, 2010 Jan 21.
Article in English | MEDLINE | ID: mdl-20098681

ABSTRACT

A key question in understanding AD is whether extracellular Abeta deposition of parenchymal amyloid plaques or intraneuronal Abeta accumulation initiates the AD process. Amyloid precursor protein (APP) is endocytosed from the cell surface into endosomes where it is cleaved to produce soluble Abeta which is then released into the brain interstitial fluid. Intraneuronal Abeta accumulation is hypothesized to predominate from the neuronal uptake of this soluble extracellular Abeta rather than from ER/Golgi processing of APP. We demonstrate that substitution of the two adjacent histidine residues of Abeta40 results in a significant decrease in its binding with PC12 cells and mouse cortical/hippocampal neurons. These substitutions also result in a dramatic enhancement of both thioflavin-T positive fibril formation and binding to preformed Abeta fibrils while maintaining its plaque-binding ability in AD transgenic mice. Hence, alteration of the histidine domain of Abeta prevented neuronal binding and drove Abeta to enhanced fibril formation and subsequent amyloid plaque deposition--a potential mechanism for removing toxic species of Abeta. Substitution or even masking of these Abeta histidine residues might provide a new therapeutic direction for minimizing neuronal uptake and subsequent neuronal degeneration and maximizing targeting to amyloid plaques.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Cerebral Cortex/metabolism , Hippocampus/metabolism , Neurons/metabolism , Amino Acid Sequence , Amyloid beta-Peptides/chemistry , Animals , Cerebral Cortex/pathology , Hippocampus/pathology , Mice , Mice, Transgenic , Molecular Sequence Data , PC12 Cells , Rats , Spectrometry, Fluorescence , Surface Plasmon Resonance
6.
Biochemistry ; 48(43): 10405-15, 2009 Nov 03.
Article in English | MEDLINE | ID: mdl-19775170

ABSTRACT

Several different monoclonal antibodies (mAbs) have been actively developed in the field of Alzheimer's disease (AD) for basic science and clinical applications; however, the binding kinetics of many of the mAbs with the beta-amyloid peptides (Abeta) are poorly understood. A panel of mAbs with different Abeta recognition sites, including our plaque-binding antibody (IgG4.1), a peptide-capturing antibody (11A50), and two classical mAbs (6E10 and 4G8) used for immunohistochemistry, were chosen for characterization of their kinetics of binding to monomeric and fibrillar forms of Abeta40 using surface plasmon resonance and their amyloid plaque binding ability in AD mouse brain sections using immunohistochemistry. The plaque-binding antibody (IgG4.1) with epitope specificity of Abeta(2-10) showed a weaker affinity (512 nM) for monomeric Abeta40 but a higher affinity (1.5 nM) for Abeta40 fibrils and labeled dense core plaques better than 6E10 as determined by immunohistochemistry. The peptide-capturing antibody (11A50) showed preferential affinity (32.5 nM) for monomeric Abeta40 but did not bind to Abeta40 fibrils, whereas antibodies 6E10 and 4G8 had moderate affinity for monomeric Abeta40 (22.3 and 30.1 nM, respectively). 4G8, which labels diffuse plaques better than 6E10, had a higher association rate constant than 6E10 but showed similar association and dissociation kinetics compared to those of 11A50. Enzymatic digestion of IgG4.1 to the F(ab')(2)4.1 fragments or their polyamine-modified derivatives that enhance blood-brain barrier permeability did not affect the kinetic properties of the antigen binding site. These differences in kinetic binding to monomeric and fibrillar Abeta among various antibodies could be utilized to distinguish mAbs that might be useful for immunotherapy or amyloid plaque imaging versus those that could be utilized for bioanalytical techniques.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/immunology , Amyloid beta-Peptides/metabolism , Antibodies, Monoclonal/metabolism , Surface Plasmon Resonance/methods , Alzheimer Disease/immunology , Animals , Antibodies, Monoclonal/immunology , Epitope Mapping , Immunohistochemistry , Kinetics , Mice , Mice, Inbred C57BL , Mice, Transgenic , Protein Binding
7.
Pharm Res ; 25(11): 2674-84, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18712585

ABSTRACT

PURPOSE: To design a smart nano-vehicle (SNV) capable of permeating the blood-brain barrier (BBB) to target cerebrovascular amyloid formed in both Alzheimer's disease (AD) and cerebrovascular amyloid angiopathy (CAA). METHODS: SNV consists of a chitosan polymeric core prepared through ionic gelation with tripolyphosphate. A polyamine modified F(ab') portion of IgG4.1, an anti-amyloid antibody, was coated as a biosensor on the SNV surface. A similar polymeric core coated with bovine serum albumin (BSA) served as a control nano-vehicle (CNV). The BBB uptake of (125)I-SNVs and (125)I-CNVs was evaluated in mice. The uptake and transcytosis of SNVs and CNVs across bovine brain microvascular endothelial cells (BBMECs) was evaluated using flow cytometry and confocal microscopy. RESULTS: Plasma clearance of (125)I-SNVs was nine times higher than that of the (125)I-CNVs. However, the uptake of (125)I-SNVs in various brain regions was about 8 to 11 times higher than that of (125)I-CNVs. The uptake of FITC-BSA loaded SNVs in BBMECs was twice the uptake of FITC-BSA loaded CNVs. Confocal micrographs demonstrated the uptake and transcytosis of Alexa Fluor 647 labeled SNVs, but not CNVs, across the BBMEC monolayer. CONCLUSIONS: SNVs are capable of carrying a payload of model protein across the BBB to target cerebral amyloid.


Subject(s)
Alzheimer Disease/metabolism , Amyloid/metabolism , Blood-Brain Barrier , Brain/blood supply , Brain/metabolism , Cerebral Amyloid Angiopathy/metabolism , Nanoparticles , Animals , Cattle , Cells, Cultured , Chitosan/administration & dosage , Female , Mice , Pharmaceutical Vehicles
8.
Pharm Res ; 25(8): 1861-72, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18443900

ABSTRACT

PURPOSE: The lack of an in vivo diagnostic test for AD has prompted the targeting of amyloid plaques with diagnostic imaging probes. We describe the development of a contrast agent (CA) for magnetic resonance microimaging that utilizes the F(ab')2 fragment of a monoclonal antibody raised against fibrillar human Abeta42 METHODS: This fragment is polyamine modified to enhance its BBB permeability and its ability to bind to amyloid plaques. It is also conjugated with a chelator and gadolinium for subsequent imaging of individual amyloid plaques RESULTS: Pharmacokinetic studies demonstrated this 125I-CA has higher BBB permeability and lower accumulation in the liver and kidney than F(ab')2 in WT mice. The CA retains its ability to bind Abeta40/42 monomers/fibrils and also binds to amyloid plaques in sections of AD mouse brain. Intravenous injection of 125I-CA into the AD mouse demonstrates targeting of amyloid plaques throughout the cortex/hippocampus as detected by emulsion autoradiography. Incubation of AD mouse brain slices in vitro with this CA resulted in selective enhancement on T1-weighted spin-echo images, which co-register with individual plaques observed on spatially matched T2-weighted spin-echo image CONCLUSIONS: Development of such a molecular probe is expected to open new avenues for the diagnosis of AD.


Subject(s)
Alzheimer Disease/pathology , Amyloid beta-Peptides/immunology , Contrast Media , Heterocyclic Compounds , Organometallic Compounds , Peptide Fragments/immunology , Plaque, Amyloid/pathology , Polyamines , Animals , Chromatography, Paper , Contrast Media/chemical synthesis , Contrast Media/pharmacokinetics , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/pharmacokinetics , Humans , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fragments , Immunoglobulin G/immunology , Mice , Mice, Transgenic , Organometallic Compounds/chemical synthesis , Organometallic Compounds/pharmacokinetics
9.
J Neurochem ; 102(2): 420-33, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17596213

ABSTRACT

Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab')(2) fragment of a monoclonal antibody against fibrillar human Abeta42 that is polyamine (p)-modified has increased permeability at the blood-brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer's disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab')(2)4.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.


Subject(s)
Alzheimer Disease/therapy , Amyloid beta-Peptides/immunology , Immunoglobulin Fragments/immunology , Immunoglobulin Fragments/metabolism , Immunotherapy/methods , Peptide Fragments/immunology , Plaque, Amyloid/immunology , Alzheimer Disease/immunology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/antagonists & inhibitors , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/therapeutic use , Binding, Competitive/immunology , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/immunology , Cell Line, Tumor , Electrophoresis, Polyacrylamide Gel , Humans , Immunoglobulin Fragments/therapeutic use , Immunoglobulin G/immunology , Immunoglobulin G/metabolism , Immunoglobulin G/therapeutic use , Immunotherapy/trends , Injections, Intravenous , Isoelectric Focusing , Mice , Mice, Transgenic , Peptide Fragments/antagonists & inhibitors , Peptide Hydrolases/chemistry , Plaque, Amyloid/drug effects , Protein Binding/immunology , Protein Transport/immunology , Radioligand Assay , Receptors, Immunologic/drug effects , Receptors, Immunologic/metabolism
10.
Biochemistry ; 45(10): 3386-95, 2006 Mar 14.
Article in English | MEDLINE | ID: mdl-16519533

ABSTRACT

Alpha-synuclein is a presynaptic protein, the A53T and A30P mutants of which are linked independently to early-onset familial Parkinson's disease. The association of wild-type alpha-synuclein with lipid membranes was characterized previously by electron spin resonance (ESR) spectroscopy with spin-labeled lipids [Ramakrishnan, M., Jensen, P. H., and Marsh, D. (2003) Biochemistry 42, 12919-12926]. Here, we study the interaction of the A53T and A30P alpha-synuclein mutants and a truncated form that lacks the acidic C-terminal domain with phosphatidylglycerol bilayer membranes, using anionic phospholipid spin labels. The strength of the interaction with phosphatidylglycerol membranes lies in the order: wild type approximately truncated > A53T > A30P > fibrils approximately 0, and only the truncated form interacts with phosphatidylcholine membranes. The selectivity of the interaction of the mutant alpha-synucleins with different spin-labeled lipid species is reduced considerably, relative to the wild-type protein, whereas that of the truncated protein is increased. Polarized infrared (IR) spectroscopy is used to study the interactions of the wild-type and truncated proteins with aligned lipid membranes and additionally to characterize the fibrillar form. Wild-type alpha-synuclein is natively unfolded in solution and acquires secondary structure upon binding to membranes containing phosphatidylglycerol. Up to 30-40% of the amide I band intensity of the membrane-bound wild-type and truncated proteins is attributable to beta-sheet structure, at the surface densities used for IR spectroscopy. The remainder is alpha-helix and residual unordered structure. Fibrillar alpha-synuclein contains 62% antiparallel beta-sheet and is oriented on the substrate surface but does not interact with deposited lipid membranes. The beta-sheet secondary-structural elements of the wild-type and truncated proteins are partially oriented on the surface of membranes with which they interact.


Subject(s)
Electron Spin Resonance Spectroscopy/methods , Lipid Bilayers/chemistry , Membranes/chemistry , Spectrophotometry, Infrared/methods , alpha-Synuclein/chemistry , Circular Dichroism , Humans , Lipid Bilayers/metabolism , Lipids/chemistry , Membranes/metabolism , Phosphatidylcholines/chemistry , Phosphatidylglycerols , Protein Binding , Protein Conformation , Proteins/chemistry , Proteins/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Spin Labels , Titrimetry , alpha-Synuclein/genetics , alpha-Synuclein/metabolism
11.
Biochemistry ; 44(9): 3515-23, 2005 Mar 08.
Article in English | MEDLINE | ID: mdl-15736961

ABSTRACT

The outer-membrane proteins OmpA and FhuA of Escherichia coli are monomeric beta-barrels of widely differing size. Polarized attenuated total reflection infrared spectroscopy has been used to determine the orientation of the beta-barrels in phosphatidylcholine host matrices of different lipid chain lengths. The linear dichroism of the amide I band from OmpA and FhuA in hydrated membranes generally increases with increasing chain length from diC(12:0) to diC(17:0) phosphatidylcholine, in both the fluid and gel phases. Measurements of the amide I and amide II dichroism from dry samples are used to deduce the strand tilt (beta = 46 degrees for OmpA and beta = 44.5 degrees for FhuA). These values are then used to deduce the order parameters, P(2)(cos alpha), of the beta-barrels from the amide I dichroic ratios of the hydrated membranes. The orientational ordering of the beta-barrels and their assembly in the membrane are discussed in terms of hydrophobic matching with the lipid chains.


Subject(s)
Bacterial Outer Membrane Proteins/chemistry , Escherichia coli Proteins/chemistry , Membrane Lipids/chemistry , Receptors, Virus/chemistry , Amides , Bacterial Outer Membrane Proteins/metabolism , Cell Membrane/chemistry , Cell Membrane/metabolism , Circular Dichroism , Escherichia coli Proteins/metabolism , Hydrophobic and Hydrophilic Interactions , Iron/chemistry , Iron/metabolism , Lipid Bilayers/chemistry , Models, Chemical , Phosphatidylcholines/chemistry , Protein Structure, Secondary , Receptors, Cell Surface/chemistry , Receptors, Cell Surface/metabolism , Receptors, Virus/metabolism
12.
Biochemistry ; 43(37): 11630-6, 2004 Sep 21.
Article in English | MEDLINE | ID: mdl-15362847

ABSTRACT

The interaction of spin-labeled lipids with beta-barrel transmembrane proteins has been studied by the electron spin resonance (ESR) methods developed for alpha-helical integral proteins. The outer membrane protein OmpA and the ferrichrome-iron receptor FhuA from the outer membrane of Escherichia coli were reconstituted in bilayers of dimyristoylphosphatidylglycerol. The ESR spectra from phosphatidylglycerol spin labeled on the 14-C atom of the sn-2 chain contain a second component from motionally restricted lipids contacting the intramembranous surface of the beta-barrel, in addition to that from the fluid bilayer lipids. The stoichiometry of motionally restricted lipids, 11 and 32 lipids/monomer for OmpA and FhuA, respectively, is constant irrespective of the total lipid/protein ratio. It is proportional to the number of transmembrane beta-strands, eight for OmpA and 22 for FhuA, and correlates reasonably well with the intramembranous perimeter of the protein. Spin-labeled lipids with different polar headgroups display a differential selectivity of interaction with the two proteins. The more pronounced pattern of lipid selectivity for FhuA than for OmpA correlates with the preponderance of positively charged residues facing the lipids in the extensions of the beta-sheet and shorter interconnecting loops on the extracellular side of FhuA.


Subject(s)
Bacterial Outer Membrane Proteins/chemistry , Escherichia coli Proteins/chemistry , Escherichia coli/chemistry , Lipids/chemistry , Protein Structure, Tertiary , Receptors, Virus/chemistry , Spin Labels , Bacterial Outer Membrane Proteins/metabolism , Electron Spin Resonance Spectroscopy , Escherichia coli/metabolism , Escherichia coli Proteins/metabolism , Lipid Bilayers/chemistry , Lipid Bilayers/metabolism , Lipid Metabolism , Models, Molecular , Molecular Sequence Data , Protein Structure, Secondary , Receptors, Virus/metabolism , Temperature
13.
Biochemistry ; 42(44): 12919-26, 2003 Nov 11.
Article in English | MEDLINE | ID: mdl-14596606

ABSTRACT

Alpha-synuclein is a small presynaptic protein, which is linked to the development of Parkinson's disease. Alpha-synuclein partitions between cytosolic and vesicle-bound states, where membrane binding is accompanied by the formation of an amphipathic helix in the N-terminal section of the otherwise unstructured protein. The impact on alpha-synuclein of binding to vesicle-like liposomes has been studied extensively, but far less is known about the impact of alpha-synuclein on the membrane. The interactions of alpha-synuclein with phosphatidylglycerol membranes are studied here by using spin-labeled lipid species and electron spin resonance (ESR) spectroscopy to allow a detailed analysis of the effect on the membrane lipids. Membrane association of alpha-synuclein perturbs the ESR spectra of spin-labeled lipids in bilayers of phosphatidylglycerol but not of phosphatidylcholine. The interaction is inhibited at high ionic strength. The segmental motion is hindered at all positions of spin labeling in the phosphatidylglycerol sn-2 chain, while still preserving the chain flexibility gradient characteristic of fluid phospholipid membranes. Direct motional restriction of the lipid chains, resulting from penetration of the protein into the hydrophobic interior of the membrane, is not observed. Saturation occurs at a protein/lipid ratio corresponding to approximately 36 lipids/protein added. Alpha-synuclein exhibits a selectivity of interaction with different phospholipid spin labels when bound to phosphatidylglycerol membranes in the following order: stearic acid > cardiolipin > phosphatidylcholine > phosphatidylglycerol approximately phosphatidylethanolamine > phosphatidic acid approximately phosphatidylserine > N-acyl phosphatidylethanolamine > diglyceride. Accordingly, membrane-bound alpha-synuclein associates at the interfacial region of the bilayer where it may favor a local concentration of certain phospholipids.


Subject(s)
Lipid Bilayers/chemistry , Nerve Tissue Proteins/chemistry , Phosphatidylglycerols/chemistry , Spin Labels , Electron Spin Resonance Spectroscopy , Humans , Hydrophobic and Hydrophilic Interactions , Models, Chemical , Phosphatidylcholines/chemistry , Phosphoproteins/chemistry , Protein Binding , Recombinant Proteins/chemistry , Static Electricity , Synucleins , Titrimetry , alpha-Synuclein
SELECTION OF CITATIONS
SEARCH DETAIL
...